

## DCVMN History Links

### 2000

WHO meeting of International Public Sector Vaccinology Institutions in Geneva in March 2000, called vaccine manufacturers from developing countries to form a constituency and holds 1st AGM in Noordwijk.

Source : <https://pubmed.ncbi.nlm.nih.gov/11672886/>

Structure of DCVMN was further developed at the WHO meeting in November 2000 for Developing Country Vaccine Producers at RIVM, Bilthoven, The Netherlands.

Source : <https://pubmed.ncbi.nlm.nih.gov/11672886/>

### 2001

DCVMN officially established at the Hotel Oranje in Noordwijk at the 2001 Partner's meeting of the Global Alliance for Vaccines and Immunisation (GAVI).

Source: <https://dare.uva.nl/search?identifier=8449dc0a-363f-4601-b528-2ee53f5812eb>

DCVMN met on 26–27 April 2001 in Bandung, Indonesia, formalizing strategic objectives and governance and grows to 20 members.

Source : <https://pubmed.ncbi.nlm.nih.gov/11672886/>

### 2002

DCVMN members are engaged in the Meningitis Vaccine Project at this time.

Source : <https://www.who.int/wer/2002/en/wer7737.pdf>

DCVMN had 13 members

Source : list of participants 2002 AGM.

### 2004

Success in increasing access to HepB and Hib containing DPT combination vaccines with the help from technology transfer from The Netherlands Vaccine Institute (NVI) to three DCVMN member companies: Bio Farma, Serum Institute of India and Biological E.

Source : <https://pubmed.ncbi.nlm.nih.gov/18294742/>

DCVMN participation in the WHO Workshop on Intellectual Property Rights and Vaccines in Developing Countries (19 - 20 April 2004, Geneva). DCVMN president gives a presentation on Intellectual Property Rights & Intellectual Property Rights & Vaccines in Developing Countries Vaccines in Developing Countries

Source: <https://www.who.int/intellectualproperty/events/en/S.Jadhav.pdf>

DCVMN had 19 members.

Source: <https://www.who.int/intellectualproperty/events/en/S.Jadhav.pdf>

## 2005

Panacea Biotec developed and launched the first fully liquid pentavalent vaccine.

Source: <https://pubmed.ncbi.nlm.nih.gov/23598479/>

DCVMN had 29 members.

Source : list of participants 2005 AGM.

## 2006

DCVMN becomes a member of the Global Action Plan for Influenza Vaccines. In response to the human-to-human transmission of H5N1, WHO developed a project to strengthen the capacity of developing countries to produce influenza vaccine. WHO provided seed grants for this purpose to 11 DCVMs

Source : <https://dare.uva.nl/search?identifier=8449dc0a-363f-4601-b528-2ee53f5812eb>

## 2007

The Global Pandemic Influenza Action Plan to increase vaccine supply of WHO aims to close the current influenza vaccine production gap of several billion doses. WHO has taken recent steps to engage DCVM: six members in Brazil, India, Indonesia, Mexico, Thailand and Viet Nam were awarded grants in 2007 for technology transfer to establish manufacturing capacity for influenza vaccine.

Source: <https://dare.uva.nl/search?identifier=8449dc0a-363f-4601-b528-2ee53f5812eb>

## 2008

DCVMN members (SII, CNBG, Panacea, Beijing Minhai) are engaged in the Sabin-IPV Project. The NVI /RIVM, upon request of WHO, started to develop such a *Sabin-based inactivated polio vaccine* process for technology transfer.

Source: <https://dare.uva.nl/search?identifier=8449dc0a-363f-4601-b528-2ee53f5812eb>  
<https://polioeradication.org/news-post/polio-vaccine-technology-transfer-continues/>

During the 3rd Regional Pneumococcal Symposium in Istanbul (13-14 February), DCVMN president Dr Homma gives a presentation on DCVMN Pneumococcal Vaccine Development Projects. DCVMN had 19 members in 2008, with 7 prequalified members. One priority for DCVMN is to accelerate the incorporation of pneumococcal vaccine production in DCVMN countries.

Source: [https://www.sabin.org/sites/sabin.org/files/akira\\_homma\\_ppt\\_readonly.pdf](https://www.sabin.org/sites/sabin.org/files/akira_homma_ppt_readonly.pdf)

## 2009

H1N1 Pandemic: three DCVMN members from India readied the vaccine for global use in a record time of 9 months

Source: <https://pubmed.ncbi.nlm.nih.gov/24476201/>

PAHO adopted a resolution in 1993 calling for the elimination of rubella and CRS in the Americas by 201 Eradication of Rubella and CRS in the region of the Americas with the help of the consitant

supply of DCVM (SII) Rubella containing vaccines. The last endemic case was observed in February 2009, which was 10 months before the target.

Source: <https://pubmed.ncbi.nlm.nih.gov/24476201/>

## **2010**

Through the Meningitis Vaccine Project (PATH/WHO/US CBER), licensing and prequalification in 2010 of a group A meningitis vaccine produced by a SII destined for use in Sub-Saharan Africa (100 million people vaccinated and 94% drop in incidences during meningitis season in 2012)

Source: <https://www.path.org/articles/about-meningitis-vaccine-project/>

## **2011**

India, once known as the world's epicenter of polio, has successfully achieved one year polio-free since its last case, recorded on 13 January 2011. Panacea Biotec, a member of DCVMN, contributed by producing and supplying more than 9.2 billion doses of OPV over two decades (1990–2011).

Source : <https://pubmed.ncbi.nlm.nih.gov/23598479/>